Zentalis Pharmaceuticals Income Statement (2019-2026) | ZNTL

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
45.20M45.49M45.58M56.97M57.00M59.28M59.44M70.60M70.64M70.77M71.01M71.11M71.15M71.28M71.95M72.14M72.25M69.09M71.16M71.67M
Revenue & cost
Revenue (Quarter)
40.56M26.86M
Operating items
Research & Development (Quarter)
54.00M38.44M46.11M43.83M42.18M40.62M48.58M42.68M46.77M51.56M49.59M48.39M36.82M32.97M27.25M27.61M22.95M29.49M28.72M35.16M
Selling, General & Administrative (Quarter)
8.87M9.75M11.77M19.64M12.01M11.14M16.37M15.66M15.95M16.36M15.74M16.76M14.61M40.01M10.58M8.45M10.78M7.91M9.14M9.23M
Restructuring Costs (Quarter)
7.80M
Other Operating Expenses (Quarter)
45.57M3.74M-0.00M
Operating Expenses (Quarter)
62.87M48.19M57.88M63.46M54.19M51.75M64.95M103.92M62.72M67.92M65.33M65.15M51.43M76.71M45.62M36.06M33.73M37.39M37.85M44.39M
Operating Income (Quarter)
-62.87M-48.19M-57.88M-63.46M-54.19M-51.75M-64.95M-103.92M-62.72M-67.92M-24.77M-65.15M-51.43M-49.85M-45.62M-36.06M-33.73M-37.39M-37.85M-44.39M
EBIT (Quarter)
-62.87M-48.19M-57.88M-63.46M-54.19M-51.75M-64.95M-103.92M-62.72M-67.92M-24.77M-65.15M-51.43M-49.85M-45.62M-36.06M-33.73M-37.39M-37.85M-44.39M
Non-operating items
Interest & Investment Income (Quarter)
0.10M0.09M0.43M0.42M1.91M3.23M4.11M4.45M7.21M6.85M34.95M-22.86M11.25M2.17M-2.66M9.18M7.04M2.62M2.62M2.24M
Other Non Operating Income (Quarter)
51.58M
Net income details
EBT (Quarter)
-11.19M-48.10M-57.45M-63.04M-52.29M-48.52M-60.84M-99.47M-55.51M-61.07M10.18M-88.01M-40.19M-47.68M-48.28M-26.87M-26.69M-34.77M-35.23M-42.15M
Tax Provisions (Quarter)
-0.70M0.16M0.03M0.02M-0.16M-0.36M0.11M-0.60M0.03M-0.14M0.14M0.27M-0.03M-0.20M0.44M0.12M0.14M
Profit After Tax (Quarter)
-4.19M-50.06M-59.24M-68.39M-54.40M-54.97M-63.22M-112.56M-55.53M-60.94M10.04M-88.28M-40.16M-47.50M-48.28M-26.87M-26.69M-35.22M-35.35M-42.29M
Income from Non-Controlling Interests (Quarter)
-6.30M-0.04M-0.16M-0.04M-0.10M-0.01M-0.04M-0.04M-0.01M-0.02M-0.03M
Income from Continuing Operations (Quarter)
-10.49M-48.26M-57.49M-63.05M-52.13M-48.16M-60.95M-98.86M-55.54M-60.94M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M-42.29M
Consolidated Net Income (Quarter)
-10.49M-48.26M-57.49M-63.05M-52.13M-48.16M-60.95M-98.86M-55.54M-60.94M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M-42.29M
Income towards Parent Company (Quarter)
-10.49M-48.26M-57.49M-63.05M-52.13M-48.16M-60.95M-98.86M-55.54M-60.94M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M-42.29M
Net Income towards Common Stockholders (Quarter)
-10.49M-48.26M-57.49M-63.05M-52.13M-48.16M-60.95M-98.86M-55.54M-60.94M10.04M-88.28M-40.16M-47.47M-48.28M-26.87M-26.69M-35.22M-35.35M-42.29M
Additional items
EPS (Basic) (Quarter)
-0.24-1.13-1.27-1.23-0.92-0.91-1.03-1.63-0.79-0.930.14-1.24-0.56-0.67-0.67-0.37-0.37-0.49-0.50-0.59
EPS (Diluted) (Quarter)
-0.24-1.13-1.27-1.23-0.92-0.91-1.03-1.63-0.79-0.930.14-1.24-0.56-0.67-0.67-0.37-0.37-0.49-0.50-0.59
Shares Outstanding (Quarter)
44.61M42.69M45.24M51.12M56.81M52.86M59.28M60.79M70.61M65.41M70.90M71.04M71.11M71.08M71.68M71.99M72.14M71.87M70.26M71.33M
Shares Outstanding (Diluted) (Quarter)
44.61M42.69M45.24M51.12M56.81M52.86M59.28M60.79M70.61M65.41M71.19M71.04M71.11M71.08M71.68M71.99M72.14M71.87M70.26M71.33M
EBITDA (Quarter)
-62.87M-48.19M-57.88M-63.46M-54.19M-51.75M-64.95M-103.92M-62.72M-67.92M-24.77M-65.15M-51.43M-49.85M-45.62M-36.06M-33.73M-37.39M-37.85M-44.39M
Interest Expenses (Quarter)
0.91M6.80M6.80M74.25M24.74M70.05M68.34M6.40M66.07M63.64M18.62M6.50M58.86M57.08M14.83M0.01M51.70M49.88M
Tax Rate (Quarter)
6.23-0.33-0.06-0.030.300.74-0.180.61-0.060.221.40-0.300.070.43-1.27-0.34-0.33